Patents by Inventor Maria Oksana Bachynsky

Maria Oksana Bachynsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185588
    Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 30, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20190117775
    Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20180153998
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20170266286
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 21, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Patent number: 9642911
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 9, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20150057296
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20150044287
    Abstract: There is provided a film coated pharmaceutical composition comprising 5?-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400?), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. This tablet disintegrates in water at 37┬░ C. in a USP Disintegration Apparatus in less than 2 minutes, preferably 1 minute and have a hardness of 8-13 strong Cobb-Units.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Mohammad Rashed, Navnit Hargovindas Shah
  • Patent number: 8889109
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: November 18, 2014
    Assignee: Hoffman-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20110027374
    Abstract: There is provided a film coated pharmaceutical composition comprising 5?-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400?), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Ludiflash® or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet.
    Type: Application
    Filed: November 17, 2009
    Publication date: February 3, 2011
    Inventors: Maria Oksana Bachynsky, Mohammad Rashed, Paul Anthony Samtak, Navnit Hargovindas Shah
  • Publication number: 20080146591
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Application
    Filed: December 11, 2007
    Publication date: June 19, 2008
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Publication number: 20080085310
    Abstract: There is provided a film coated pharmaceutical composition comprising 5?-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400?), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. This tablet disintegrates in water at 37┬░ C. in a USP Disintegration Apparatus in less than 2 minutes, preferably 1 minute and have a hardness of 8-13 strong Cobb-Units.
    Type: Application
    Filed: September 25, 2007
    Publication date: April 10, 2008
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Mohammad Rashed, Navnit Hargovindas Shah